Valpione, SaraMundra, Piyushkumar A.Galvani, ElenaCampana, Luca G.; orcid: 0000-0002-8466-8459Lorigan, Paul; orcid: 0000-0002-8875-2164De Rosa, Francesco; orcid: 0000-0003-0511-1298Gupta, AvinashWeightman, JohnMills, SarahDhomen, NathalieMarais, Richard; orcid: 0000-0001-7484-4183; email: richard.marais@cruk.manchester.ac.uk2021-07-232021-07-232021-07-022020-07-30Nature Communications, volume 12, issue 1, page 4098http://hdl.handle.net/10034/625362From Springer Nature via Jisc Publications RouterHistory: received 2020-07-30, accepted 2021-06-09, registration 2021-06-16, pub-electronic 2021-07-02, online 2021-07-02, collection 2021-12Publication status: PublishedFunder: Harry J. Lloyd Charitable Trust; doi: https://doi.org/10.13039/100005976; Grant(s): Career Development AwardFunder: Cancer Research UK (CRUK); doi: https://doi.org/10.13039/501100000289; Grant(s): A27412, A22902Funder: Wellcome Trust (Wellcome); doi: https://doi.org/10.13039/100004440; Grant(s): 100282/Z/12/ZAbstract: Tumor infiltration by T cells is paramount for effective anti-cancer immune responses. We hypothesized that the T cell receptor (TCR) repertoire of tumor infiltrating T lymphocytes could therefore be indicative of the functional state of these cells and determine disease course at different stages in cancer progression. Here we show that the diversity of the TCR of tumor infiltrating T cell at baseline is prognostic in various cancers, whereas the TCR clonality of T cell infiltrating metastatic melanoma pre-treatment is predictive for activity and efficacy of PD1 blockade immunotherapy.Licence for this article: http://creativecommons.org/licenses/by/4.0/Article/631/67/1059/2325/631/114/2415/692/53/2423/692/4028/67/580/38/91/38/23articlearticle2021-07-23